Table 1.
Survey Respondent Characteristics by Parent Study XR-NTX Induction Success
| “Study Completers” received all 3 injections (N= 27) |
Received 1–2 injections (N=11) |
Unsuccessful induction (0 injections) (N= 19) |
P | |
|---|---|---|---|---|
| Male | 24 (88.9%) | 10 (90.9%) | 16 (84.2%) | ns |
| Age, years (SD) | 33.4 (13.2) | 33.4 (10.1) | 39.2 (12.1) | ns |
| Caucasian | 16 (59.3%) | 9 (81.8%) | 9 (47.4%) | ns |
| Hispanic | 7 (25.9%) | 2 (18.2%) | 5 (26.3%) | ns |
| African American | 3 (11.1%) | 0 | 3 (15.8%) | ns |
| Asian | 0 | 0 | 2 (10.5%) | ns |
| Native American | 0 | 0 | 0 | ns |
| Other | 1 (3.7%) | 0 | 0 | ns |
| Heroin as primary opioid used | 11 (40.7%) | 5 (45.5%) | 16 (84.2%) | 0.01 (1=2<3) |
| Marijuana use | 14 (51.9%) | 3 (27.3%) | 4 (21.1%) | 0.064 (1>3) |
| Severity of Use | ||||
| MEQ*/day mg (SD) | 251 (114) | 249 (140) | 318 (241) | ns |
| Age of regular use (years, SD) | 24.8 (9.9) | 27.7 (6.9) | 29.1 (9.3) | ns |
| Years of regular use at enrollment (SD) | 8.6 (10.9) | 5.6 (4.3) | 10.1 (8.5) | ns |
| Injection as primary route ingestion | 2 (7.4%) | 2 (18.2%) | 9 (47.4%) | 0.006 (1=2<3) |
*
MEQ= morphine equivalent doses